Navigation Links
Safety of Labor-Delaying Drugs Questioned
Date:3/6/2009

The dilemma, researchers say, is whether or not to treat at all

FRIDAY, March 6 (HealthDay News) -- Certain drugs used to delay preterm labor can cause serious complications in women, a European study finds.

Doctors use tocolytic drugs to delay labor for up to 48 hours. In this way, they gain time to allow steroids to hasten fetal lung development. These delays also enable the expectant mother to be transferred to a medical facility with a neonatal intensive care unit, according to background information in the study.

The most widely used tocolytic drugs include beta agonists and nifedipine (which relax smooth muscles, including the uterus), and atosiban and indometacin (which inhibit hormones involved in labor), according to the study. However, the use of these drugs is controversial, because it's not clear whether tocolysis is safe for both mother and baby.

The researchers analyzed the rate of serious complications in 1,920 women treated with tocolytic drugs for preterm labor at 28 hospitals in the Netherlands and Belgium. Atosiban was the most commonly used drug (42 percent), followed by nifedipine (34 percent), beta agonists (14 percent), and indometacin (8 percent).

The overall incidence of adverse effects was 0.7 percent, but combined or single treatment with a beta agonist led to a higher incidence of serious drug reactions. There were no reports of serious reactions when women received atosiban or indometacin.

Combined or single treatment with beta agonists should be discouraged, concluded the researchers. They also recommended further trials to test the safety and effectiveness of nifedipine and atosiban.

In an accompanying editorial, the researchers said their study is a reminder that the decision to use tocolysis shouldn't be taken lightly.

"After 30 years of research, we still do not know whether tocolysis benefits the fetus, so the choice of which drug to use remains a secondary question. The real dilemma is whether or not we should treat at all," they wrote. The long-held belief that "keeping the baby inside longer must be a good thing" needs to be reevaluated, they said.

The study was published March 6 online in the BMJ.

A study released last year found that nifedipine was no more effective than placebo at preventing preterm labor. The U.S. study, which included 71 women, was published in the journal Obstetrics & Gynecology.

More information

The U.S. National Institute on Child Health and Human Development has more about preventing preterm birth.



-- Robert Preidt



SOURCE: BMJ, news release, March 6, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. AdvaMed Available for Comment on Medical Device Safety Act
2. AdvaMed Response to the Medical Device Safety Act
3. bioPoint(TM) PID Wristband Software Improves Patient Identification Accuracy and Safety
4. New Esco White Papers Document Hydrogen Peroxide Decontamination of Biological Safety Cabinets
5. Number of cardiovascular risk factors could determine safety of intravenous gammaglobulin treatment
6. Zebra Technologies Introduces New Soft Infant Wristbands for Improved Safety and Comfort
7. Travel Safety Can Be a Passport to Good Health
8. Main U.S. Toxics Law Failing to Ensure Safety of Thousands of Chemicals
9. Johns Hopkins safety team works to eliminate bloodstream infections in the nation and the world
10. Governor Rendell Forms Food Safety Council to Protect Public Health, Food Supply
11. Switch to Daylight Savings Time Will Launch First Annual Sedation Dentistry Safety Week Hosted by DOCS Education
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Safety of Labor-Delaying Drugs Questioned
(Date:4/25/2017)... , ... April 25, 2017 , ... ... a modern procedure that achieves results in a fraction of the time as ... Vegas, NV, with Significance Dental Specialists, now offers this revolutionary treatment with or ...
(Date:4/25/2017)... RESTON, VIRGINIA (PRWEB) , ... April 25, 2017 ... ... scientists leading the way in unveiling cutting-edge birth defects research related to Zika ... recognized by the world’s premier society for this important science. , ...
(Date:4/25/2017)... ... 2017 , ... Buyers and sellers in the thriving multi-billion dollar cannabis marketplace ... help but be heartened by the industry’s current surge. But another thing that unifies ... smell.” At last they can simply, safely and effectively end their aroma anguish ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... ... addition of predictive analytics to its patient care management module. Using this new ... before a patient has been initiated on continuous positive airway pressure (CPAP), oral, ...
(Date:4/25/2017)... ... April 25, 2017 , ... There is no better place in South Florida ... report in the May issue of Consumer Reports focused on heart health. , ... achieved during and after coronary bypass and aortic valve replacement procedures. , Consumer ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... WOONSOCKET, R.I. , April 20, 2017 /PRNewswire/ ... (NYSE: CVS), today unveiled a new store design ... new assortment of healthier food, health-focused products and ... the store to help customers discover new offerings. ... represent the next evolution of the customer experience ...
(Date:4/20/2017)... Research and Markets has announced the addition of ... Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, ... ... at US$ 7,167.6 Mn in 2015, and is expected to ... of 5.6% from 2016 to 2024. The ...
(Date:4/20/2017)... Research and Markets has announced the addition of the ... Service (Manufacturing, Research), By Country, (Brazil, Mexico, Colombia, Argentina, Chile, ... their offering. ... Latin American pharmaceutical contract manufacturing services market is anticipated to ... registration cost in Latin American countries and continuous economic growth ...
Breaking Medicine Technology: